Fusion Pharmaceuticals Inc FUSN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/15/24 EDT
21.28quote price arrow down-0.03 (-0.14%)
Volume
854,320
52 week range
2.31 - 21.55
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close21.28
  • 52 Week High21.55
  • 52 Week High Date04/04/24
  • 52 Week Low2.31
  • 52 Week Low Date09/11/23

Key Stats

  • Market Cap1.802B
  • Shares Out84.69M
  • 10 Day Average Volume1.65M
  • Dividend-
  • Dividend Yield-
  • Beta-0.69
  • YTD % Change121.44

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close21.28
  • 52 Week High21.55
  • 52 Week High Date04/04/24
  • 52 Week Low2.31
  • 52 Week Low Date09/11/23
  • Market Cap1.802B
  • Shares Out84.69M
  • 10 Day Average Volume1.65M
  • Dividend-
  • Dividend Yield-
  • Beta-0.69
  • YTD % Change121.44

RATIOS/PROFITABILITY

  • EPS (TTM)-1.47
  • P/E (TTM)-14.51
  • Fwd P/E (NTM)-14.80
  • EBITDA (TTM)-97.887M
  • ROE (TTM)-49.34%
  • Revenue (TTM)2.068M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-4,588.83%
  • Debt To Equity (MRQ)15.63%

EVENTS

  • Earnings Date05/09/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Fusion Pharmaceuticals Inc

Profile

MORE
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and...
Barbara Duncan
Independent Chairman of the Board
John Valliant Ph.D.
Chief Executive Officer, Founder, Director
Mohit Rawat
President, Chief Business Officer
John Crowley CPA
Chief Financial Officer
Eric Burak Ph.D.
Chief Technology Officer
Address
270 Longwood Rd. S
Hamilton, ON
L8P 0A6
Canada

Top Peers

SYMBOLLASTCHG%CHG
JANX
Janux Therapeutics Inc
51.86-0.79-1.50%
VERA
Vera Therapeutics Inc
46.53-1.44-3.00%
SNDX
Syndax Pharmaceuticals Inc
21.62-0.10-0.46%
INBX
Inhibrx Inc
34.74-0.24-0.69%
GERN
Geron Corp
3.45-0.19-5.22%